Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRI-Based Radiomics to Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Retrospective Study.

Journal of personalized medicine·2026
Same author

Radiomics analysis of restaging MRI for detection of pathological complete response in locally advanced rectal cancer.

European journal of radiology open·2026
Same author

Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with Lenvatinib.

Liver cancer·2026
Same author

Reproducibility of segmentation and radiomic features in contrast-enhanced CT images of early, intermediate and advanced HCC patients: a multicenter study.

European journal of radiology·2026
Same author

MRI-derived wall thickness heterogeneity in hypertrophic cardiomyopathy and in carriers of sarcomeric gene mutations.

European heart journal. Cardiovascular Imaging·2026
Same author

Photon-Counting Detector Computed Tomography and Hepatocellular Carcinoma-A Systematic Review of the Current Evidence.

Diagnostics (Basel, Switzerland)·2026
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Chemoembolization for hepatocellular carcinoma.

Riccardo Lencioni1

  • 1Division of Diagnostic Imaging and Intervention, Pisa University School of Medicine, Pisa, Italy. riccardo.lencioni@med.unipi.it

Seminars in Oncology
|August 1, 2012
PubMed
Summary
This summary is machine-generated.

Drug-eluting beads transarterial chemoembolization (DEB-TACE) combined with sorafenib shows promise for hepatocellular carcinoma (HCC). This combination therapy may improve outcomes compared to DEB-TACE alone in patients with advanced liver cancer.

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 20, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Hepatobiliary Oncology
  • Interventional Radiology
  • Molecular Targeted Therapy

Background:

  • Transcatheter arterial chemoembolization (TACE) is standard for multinodular hepatocellular carcinoma (HCC) with preserved liver function.
  • Conventional TACE offers modest survival benefits, driving research into improved strategies.
  • Drug-eluting beads (DEB) reduce toxicity compared to conventional TACE.

Purpose of the Study:

  • To investigate the efficacy and safety of combining DEB-TACE with molecular targeted agents for HCC.
  • To evaluate the potential synergistic effects of anti-angiogenic therapy with TACE-induced hypoxia.

Main Methods:

  • Phase II randomized, double-blind, placebo-controlled trial (SPACE study).
  • Concurrent administration of DEB-TACE and sorafenib versus DEB-TACE alone.
  • Assessment of safety profile, time to progression, and time to vascular invasion or extrahepatic spread.

Main Results:

  • Concurrent DEB-TACE and sorafenib demonstrated a manageable safety profile.
  • The combination therapy suggested improvements in time to progression.
  • Potential benefits observed in time to vascular invasion or extrahepatic spread compared to DEB-TACE alone.

Conclusions:

  • Concurrent DEB-TACE and sorafenib is a safe and potentially effective strategy for HCC.
  • Further phase III trials are warranted to confirm these findings.
  • Combination therapy represents a promising approach for advanced HCC management.